AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019

May 2, 2019

MONROVIA, Calif.--(BUSINESS WIRE)--May 2, 2019--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter 2019 financial results after the market closes on Thursday, May 9, 2019.

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 8597541. A live webcast of the conference call will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. The webcast will be archived on the company website for 90 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 12 candidates engineered with Xencor’s XmAb ® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit  www.xencor.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005852/en/

CONTACT: Charles Liles

626-737-8118

cliles@xencor.comMedia Contact

Jason I. Spark

Canale Communications

619-849-6005

jason@canalecomm.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Xencor, Inc.

Copyright Business Wire 2019.

PUB: 05/02/2019 04:01 PM/DISC: 05/02/2019 04:01 PM

http://www.businesswire.com/news/home/20190502005852/en